Changes in Surface Expression of Platelet Membrane Glycoproteins and Progression of Heart Transplant Vasculopathy
- 22 August 2000
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (8) , 890-897
- https://doi.org/10.1161/01.cir.102.8.890
Abstract
Background —Transplant vasculopathy is the main limiting factor of the long-term success of heart transplantation. We sought to establish the role of platelets in the development and progression of transplant vasculopathy. Methods and Results —Platelet analysis and intracoronary ultrasound examination were performed in 78 heart transplant recipients. Quantitative intracoronary ultrasound was used to define the severity of disease at baseline (48.8±4.5 months after transplantation) and at 1-year follow-up. Platelet activation was assessed with the use of immunological surface markers of activation (ligand-induced binding site 1 [LIBS-1], P-selectin, GPIIb-IIIa) and flow cytometry. We found that LIBS-1 immunoreactivity was significantly increased in patients with diffuse disease when compared with focal transplant disease (median [quartile], 27[14, 64] versus 18[7.9, 47], P =0.04). In a logistic regression model, we found that LIBS-1 was an independent predictor for the presence and progression of diffuse transplant vasculopathy ( P =0.04). Patients with enhanced LIBS-1 levels (>75% quartile) had a 3.3-fold increased relative risk (95% CI 1.8 and 18.9, P =0.002) for the presence of diffuse transplant vasculopathy. When a cutoff value of 16.5 for the level of LIBS-1 was used, patients had a 4.8-fold increased relative risk (95% CI 1.9 and 12.5, P Conclusions —Enhanced platelet activation is strongly associated with the development and progression of transplant vasculopathy. Understanding the underlying pathophysiological mechanisms might contribute to the development of treatment strategies to prevent transplant vasculopathy.Keywords
This publication has 18 references indexed in Scilit:
- Adhesion of Activated Platelets to Endothelial Cells: Evidence for a GPIIbIIIa-dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), αvβ3 Integrin, and GPIbαThe Journal of Experimental Medicine, 1998
- In‐vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β‐thalassaemia majorBritish Journal of Haematology, 1997
- INHIBITION OF PLATELET INTEGRIN GPIIbIIIa PROLONGS SURVIVAL OF DISCORDANT CARDIAC XENOGRAFTS1,2Transplantation, 1996
- Systemic but not renal production of prostacyclin is highly reduced in cyclosporin-treated heart transplant recipientstThe American Journal of Cardiology, 1993
- EVALUATION OF TICLOPIDINE, A NOVEL INHIBITOR OF PLATELET AGGREGATION, IN HEART TRANSPLANT RECIPIENTSTransplantation, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findingsJournal of the American College of Cardiology, 1988
- CYCLOSPORINE SUPPRESSION OF ENDOTHELIAL PROSTACYCLIN GENERATIONTransplantation, 1988
- Cyclosporine A enhances platelet aggregationKidney International, 1987